Status:
UNKNOWN
Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19
Lead Sponsor:
The University of Hong Kong
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
To conduct an open-label randomized controlled trial on a short course of interferon β-1b and clofazimine combination treatment for patients hospitalized for COVID-19 infection. To assess its safety a...
Detailed Description
The novel coronavirus (SARS-CoV-2), is a single-stranded RNA coronavirus. The virus was first isolated from patients presented with pneumonia in Wuhan in December 2019.Sequences of the Wuhan betacoron...
Eligibility Criteria
Inclusion
- Recruited subjects include all adult patients 18 years or above hospitalized for virologic confirmed SARS-CoV-2 infection.
- All subjects give written informed consent. For patients who are critically ill, requiring ICU, ventilation or confused, informed consent will be obtained from spouse, next-of-kin or legal guardians.
- Subjects must be available to complete the study and comply with study procedures. Willingness to allow for serum samples to be stored beyond the study period, for potential additional future testing to better characterize immune response
Exclusion
- Inability to comprehend and to follow all required study procedures.
- Allergy or severe reactions to the study drugs
- Patients taking medication that will potentially interact with l interferon beta-1b or clofazimine
- Patients with known history of severe depression
- Received an experimental agent (vaccine, drug, biologic, device, blood product, or medication) within 1 month prior to recruitment in this study or expect to receive an experimental agent during this study.
- To participate in an unrelated trial during the current clinical trial. Nevertheless, the patients have the right to withdraw from the current clinical trial to join another clinical trial.
- Have a history of alcohol or drug abuse in the last 5 years.
- Have any condition that the investigator believes may interfere with successful completion of the study
Key Trial Info
Start Date :
July 14 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 30 2021
Estimated Enrollment :
81 Patients enrolled
Trial Details
Trial ID
NCT04465695
Start Date
July 14 2020
End Date
September 30 2021
Last Update
July 15 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Hong Kong, Queen Mary Hospital
Hong Kong, Hong Kong, China, 852